Target discovery
- 1 October 2003
- journal article
- review article
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 2 (10) , 831-838
- https://doi.org/10.1038/nrd1202
Abstract
Target discovery, which involves the identification and early validation of disease-modifying targets, is an essential first step in the drug discovery pipeline. Indeed, the drive to determine protein function has been stimulated, both in industry and academia, by the completion of the human genome project. In this article, we critically examine the strategies and methodologies used for both the identification and validation of disease-relevant proteins. In particular, we will examine the likely impact of recent technological advances, including genomics, proteomics, small interfering RNA and mouse knockout models, and conclude by speculating on future trends.Keywords
This publication has 67 references indexed in Scilit:
- A Growing Network of Cancer-Susceptibility GenesNew England Journal of Medicine, 2003
- The genetics and genomics of cancerNature Genetics, 2003
- Target selection in drug discoveryNature Reviews Drug Discovery, 2003
- Inflammation and cancerNature, 2002
- Effects of β2-agonists on airway tone and bronchial responsivenessJournal of Allergy and Clinical Immunology, 2002
- Inflammation in atherosclerosisNature, 2002
- The druggable genomeNature Reviews Drug Discovery, 2002
- Systems Biology: A Brief OverviewScience, 2002
- FomivirsenDrugs of Today, 2001
- Mortality in relation to smoking: 40 years' observations on male British doctorsBMJ, 1994